Cephaloglycin

Summary

Cephaloglycin (CHEMBL1200971) is an approved small-molecule antimicrobial agent.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 405.4 Da · C18H19N3O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200971
Name	Cephaloglycin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	19150
ChEBI	CHEBI:34613
Molecular formula	C18H19N3O6S
Molecular weight	405.4
InChIKey	FUBBGQLTSCSAON-PBFPGSCMSA-N

SMILES: CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O

IUPAC name: (6R,7R)-3-(acetyloxymethyl)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin antibiotic containing at the 7β-position of the cephem skeleton an (R)-amino(phenyl)acetamido group.

Pharmacological roles (ChEBI): antimicrobial agent.

Also known as: Cefaloglicina, Cefaloglycin, Cefaloglycin dihydrate, Cefaloglycine, Cephaloglycin, Cephaloglycin anhydrous, Cephaloglycin dihydrate, Kafocin, Kefocin, CEPHALOGLYCIN, Cephaloglycine, cefaloglycin

Patent coverage: 2,179 distinct patent families (7,883 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGS1	5.23	AC50	5930	nM	CHEMBL_ACT_25205361

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).